{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:07:50Z","timestamp":1784660870259,"version":"3.55.0"},"reference-count":156,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>This Technical Report was retired April 2025.<\/jats:title>\n               <jats:p>This technical report accompanies the recommendations of the American Academy of Pediatrics for the routine use of influenza vaccine and antiviral medications in the prevention and treatment of influenza in children during the 2022 to 2023 season. The American Academy of Pediatrics recommends annual influenza vaccination of all children without medical contraindications starting at 6 months of age. Influenza vaccination is an important strategy for protecting children and the broader community as well as reducing the overall burden of respiratory illnesses when other viruses, including severe acute respiratory syndrome-coronavirus 2, are cocirculating. This technical report summarizes recent influenza seasons, morbidity and mortality in children, vaccine effectiveness, and vaccination coverage, and provides detailed guidance on storage, administration, and implementation. The report also provides a brief background on inactivated and live attenuated influenza vaccine recommendations, vaccination during pregnancy and breastfeeding, diagnostic testing, and antiviral medications for treatment and chemoprophylaxis. Updated information is provided about the 2021 to 2022 influenza season, influenza immunization rates, the effectiveness of influenza vaccination on hospitalization and mortality, available vaccines, guidance for patients with history of severe allergic reactions to prior influenza vaccinations, and strategies to promote vaccine uptake.<\/jats:p>","DOI":"10.1542\/peds.2022-059275","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T04:13:40Z","timestamp":1662437620000},"source":"Crossref","is-referenced-by-count":21,"title":["Recommendations for Prevention and Control of Influenza in Children, 2022\u20132023"],"prefix":"10.1542","volume":"150","author":[{"name":"COMMITTEE ON INFECTIOUS DISEASES","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"issue":"4","key":"2025072309471910400_B1","first-page":"e2022059274","article-title":"Policy statement. Recommendations for prevention and control of influenza in children, 2021\u20132022","volume":"150","author":"American Academy of Pediatrics, Committee on Infectious Diseases","year":"2022","journal-title":"Pediatrics"},{"issue":"10","key":"2025072309471910400_B2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.15585\/mmwr.mm7110a1","article-title":"Interim estimates of 2021\u201322 seasonal influenza vaccine effectiveness\u2014United States, February 2022","volume":"71","author":"Chung","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025072309471910400_B3","unstructured":"Centers for Disease Control and Prevention\n          . Weekly US influenza surveillance report (FluView). Available at: https:\/\/www.cdc.gov\/flu\/weekly\/. Accessed May 31, 2020"},{"issue":"10","key":"2025072309471910400_B4","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/cid\/cix1060","article-title":"Seasonal incidence of symptomatic influenza in the United States","volume":"66","author":"Tokars","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2025072309471910400_B5","doi-asserted-by":"crossref","first-page":"e20172918","DOI":"10.1542\/peds.2017-2918","article-title":"Influenza-associated pediatric deaths in the United States, 2010-2016","volume":"141","author":"Shang","year":"2018","journal-title":"Pediatrics"},{"key":"2025072309471910400_B6","article-title":"Epidemiology, clinical characteristics, and outcomes of influenza-associated hospitalizations in U.S. children over 9 seasons following the 2009 H1N1 pandemic [published online ahead of print April 19, 2022]","author":"Kamidani","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2025072309471910400_B7","doi-asserted-by":"crossref","first-page":"e2121880","DOI":"10.1001\/jamanetworkopen.2021.21880","article-title":"Rates of influenza-associated hospitalization, intensive care unit admission, and in-hospital death by race and ethnicity in the United States From 2009 to 2019","volume":"4","author":"O\u2019Halloran","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2025072309471910400_B8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M20-6306","article-title":"Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths: a systematic review","volume":"174","author":"Mackey","year":"2021","journal-title":"Ann Intern Med"},{"issue":"4","key":"2025072309471910400_B9","doi-asserted-by":"crossref","first-page":"e2020029090","DOI":"10.1542\/peds.2020-029090","article-title":"Family and child risk factors for early-life RSV illness","volume":"147","author":"Fitzpatrick","year":"2021","journal-title":"Pediatrics"},{"key":"2025072309471910400_B10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jpeds.2021.06.075","article-title":"Prevalence, risk factors, and outcomes of influenza-associated neurologic complications in children","volume":"239","author":"Antoon","year":"2021","journal-title":"J Pediatr"},{"key":"2025072309471910400_B11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jpeds.2021.07.039","article-title":"Influenza-associated neurologic complications in hospitalized children","volume":"239","author":"Frankl","year":"2021","journal-title":"J Pediatr"},{"key":"2025072309471910400_B12","unstructured":"Centers for Disease Control and Prevention\n          . Flu disparities among racial and ethnic minority groups. Available at: https:\/\/www.cdc.gov\/flu\/highrisk\/disparities-racial-ethnic-minority- groups.html. Accessed July 12, 2021"},{"key":"2025072309471910400_B13","article-title":"Vaccine effectiveness against life-threatening influenza illness in US children [published online ahead of print January 13, 2022]","author":"Olson","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2025072309471910400_B14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/jpids\/piaa017","article-title":"Vaccine effectiveness against influenza hospitalization among children in the United States, 2015-2016","volume":"10","author":"Feldstein","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"12","key":"2025072309471910400_B15","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/cid\/ciz125","article-title":"Influenza vaccine effectiveness against hospitalization in fully and partially vaccinated children in Israel: 2015-2016, 2016-2017, and 2017-2018","volume":"69","author":"Segaloff","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"13","key":"2025072309471910400_B16","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.vaccine.2020.02.031","article-title":"The impact of new universal child influenza programs in Australia: vaccine coverage, effectiveness and disease epidemiology in hospitalised children in 2018","volume":"38","author":"Blyth","year":"2020","journal-title":"Vaccine"},{"issue":"14","key":"2025072309471910400_B17","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1016\/j.vaccine.2020.02.049","article-title":"Influenza vaccine effectiveness against influenza-associated hospitalization in children: a systematic review and meta-analysis","volume":"38","author":"Kalligeros","year":"2020","journal-title":"Vaccine"},{"issue":"2","key":"2025072309471910400_B18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.vaccine.2019.10.035","article-title":"Effectiveness of influenza vaccine in children in preventing influenza associated hospitalisation, 2018\/19, England","volume":"38","author":"Pebody","year":"2020","journal-title":"Vaccine"},{"issue":"3","key":"2025072309471910400_B19","doi-asserted-by":"crossref","first-page":"e0249005","DOI":"10.1371\/journal.pone.0249005","article-title":"Influenza vaccine effectiveness against influenza A in children based on the results of various rapid influenza tests in the 2018\/19 season","volume":"16","author":"Shinjoh","year":"2021","journal-title":"PLoS One"},{"issue":"10","key":"2025072309471910400_B20","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/cid\/ciab709","article-title":"A retrospective test-negative case-control study to evaluate influenza vaccine effectiveness in preventing hospitalizations in children","volume":"73","author":"Yildirim","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2025072309471910400_B21","doi-asserted-by":"crossref","first-page":"e20164244","DOI":"10.1542\/peds.2016-4244","article-title":"Influenza vaccine effectiveness against pediatric deaths: 2010-2014","volume":"139","author":"Flannery","year":"2017","journal-title":"Pediatrics"},{"issue":"4","key":"2025072309471910400_B22","doi-asserted-by":"crossref","first-page":"e947","DOI":"10.1093\/cid\/ciab060","article-title":"Effect of vaccination on preventing influenza-associated hospitalizations among children during a severe season associated with B\/Victoria viruses, 2019-2020","volume":"73","author":"Campbell","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2025072309471910400_B23","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1093\/cid\/ciz1244","article-title":"Effects of influenza vaccination in the United States during the 2018-2019 influenza season","volume":"71","author":"Chung","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025072309471910400_B24","unstructured":"Centers for Disease Control and Prevention\n          . Estimated influenza illnesses, Medical visits, and hospitalizations averted by vaccination in the United States \u2014 2019\u20132020 influenza season. Available at: https:\/\/www.cdc.gov\/flu\/about\/burden-averted\/2019-2020.htm. Accessed May 9, 2022"},{"issue":"5","key":"2025072309471910400_B25","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/infdis\/jiu185","article-title":"Effectiveness of influenza vaccine against life-threatening RT-PCR-confirmed influenza illness in US children, 2010-2012","volume":"210","author":"Ferdinands","year":"2014","journal-title":"J Infect Dis"},{"issue":"3","key":"2025072309471910400_B26","doi-asserted-by":"crossref","first-page":"e20154643","DOI":"10.1542\/peds.2015-4643","article-title":"Hospitalization for influenza A versus B","volume":"138","author":"Tran","year":"2016","journal-title":"Pediatrics"},{"key":"2025072309471910400_B27","unstructured":"World Health Organization\n          . Recommended composition of influenza virus vaccines for use in the 2021-2022 northern hemisphere influenza season. Available at: https:\/\/www.who.int\/publications\/i\/item\/recommended- composition-of-influenza-virus- vaccines-for-use-in-the-2021-2022- northern-hemisphere-influenza-season. Accessed June 9, 2021"},{"key":"2025072309471910400_B28","unstructured":"US Food and Drug Administration\n          . Vaccines licensed for use in the United States. https:\/\/www.fda.gov\/vaccines- blood-biologics\/vaccines\/vaccines- licensed-use-united-states. Accessed April 4, 2022"},{"key":"2025072309471910400_B29","article-title":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2022\u20132023 influenza season","author":"Grohskopf","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025072309471910400_B30","volume-title":"Clinical Review: Flucelvax Quadrivalent","author":"US Food and Drug Administration","year":"2021"},{"key":"2025072309471910400_B31","unstructured":"US Food and Drug Administration\n          . Letter to Seqirus Inc. supplement approval PMR fulfilled. Available at: https:\/\/www.fda.gov\/media\/153137\/download. Accessed August 23, 2022"},{"issue":"9","key":"2025072309471910400_B32","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1097\/INF.0000000000003247","article-title":"Immunogenicity and safety of AS03-adjuvanted H5N1 influenza vaccine in children 6-35 months of age","volume":"40","author":"Kim","year":"2021","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"2025072309471910400_B33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S2213-2600(18)30108-5","article-title":"Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial","volume":"6","author":"Vesikari","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"38","key":"2025072309471910400_B34","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1016\/j.vaccine.2021.08.021","article-title":"Improved immunologic responses to heterologous influenza strains in children with low preexisting antibody response vaccinated with MF59-adjuvanted influenza vaccine","volume":"39","author":"Palladino","year":"2021","journal-title":"Vaccine"},{"issue":"47","key":"2025072309471910400_B35","doi-asserted-by":"crossref","first-page":"6930","DOI":"10.1016\/j.vaccine.2021.10.010","article-title":"Antibody responses against heterologous A\/H5N1 strains for an MF59-adjuvanted cell culture-derived A\/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects","volume":"39","author":"Chanthavanich","year":"2021","journal-title":"Vaccine"},{"key":"2025072309471910400_B36","unstructured":"US Food and Drug Administration\n          . Fluarix Quadrivalent package insert. Available at: https:\/\/www.fda.gov\/media\/79278\/download. Accessed May 9, 2022"},{"key":"2025072309471910400_B37","unstructured":"US Food and Drug Administration\n          . Flulaval Quadrivalent package insert. Available at: https:\/\/www.fda.gov\/media\/115785\/download. Accessed May 9, 2022"},{"key":"2025072309471910400_B38","unstructured":"US Food and Drug Administration\n          . Flucelvax Quadrivalent package insert. Available at: https:\/\/www.fda.gov\/media\/115862\/download. Accessed May 9, 2022"},{"key":"2025072309471910400_B39","unstructured":"US Food and Drug Administration\n          . Fluzone quadrivalent, fluzone high-dose quadrivalent, fluzone, intradermal quadrivalent, fluzone quadrivalent southern hemisphere. Available at: https:\/\/www.fda.gov\/vaccines-blood- biologics\/vaccines\/fluzone-quadrivalent. Accessed May 2, 2022"},{"issue":"3","key":"2025072309471910400_B40","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/INF.0000000000002227","article-title":"Safety and immunogenicity of a full-dose, split-virion, inactivated, quadrivalent influenza vaccine in healthy children 6-35 months of age: a randomized controlled clinical trial","volume":"38","author":"Robertson","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2025072309471910400_B41","unstructured":"US Food and Drug Administration\n          . Afluria Quadrivalent. Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/afluria-quadrivalent. Accessed June 24, 2019"},{"key":"2025072309471910400_B42","first-page":"277","article-title":"Thimerosal in vaccines","volume":"87","author":"World Health Organization, Global Advisory Committee on Vaccine Safety","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"issue":"10318","key":"2025072309471910400_B43","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/S0140-6736(21)02329-1","article-title":"Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial","volume":"398","author":"Lazarus","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"2025072309471910400_B44","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-2600(21)00557-9","article-title":"Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged \u226565 years: a phase 2, randomised, open-label study","volume":"10","author":"Izikson","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2025072309471910400_B45","doi-asserted-by":"crossref","first-page":"e20160320","DOI":"10.1542\/peds.2016-0320","article-title":"Febrile seizure risk after vaccination in children 6 to 23 months","volume":"138","author":"Duffy","year":"2016","journal-title":"Pediatrics"},{"issue":"17","key":"2025072309471910400_B46","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.2146\/news140063","article-title":"Vaccine safety signal from spontaneous system not supported by active surveillance","volume":"71","author":"Thompson","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"2025072309471910400_B47","unstructured":"Sentinel CBER\/PRISM Surveillance Report\n          . Influenza vaccines and febrile seizures in the 2013-2014 and 2014-2015 influenza seasons. Available at: https:\/\/www.sentinelinitiative.org\/sites\/default\/files\/vaccines-blood-biologics\/assessments\/Influenza-Vaccines-Febrile-Seizures-Final-Report.pdf. Accessed June 24, 2019"},{"issue":"9","key":"2025072309471910400_B48","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.vaccine.2020.01.046","article-title":"The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines","volume":"38","author":"Baker","year":"2020","journal-title":"Vaccine"},{"issue":"3","key":"2025072309471910400_B49","doi-asserted-by":"crossref","first-page":"e20191909","DOI":"10.1542\/peds.2019-1909","article-title":"Fever after influenza, diphtheria-tetanus-acellular pertussis, and pneumococcal vaccinations","volume":"145","author":"Walter","year":"2020","journal-title":"Pediatrics"},{"key":"2025072309471910400_B50","unstructured":"Centers for Disease Control and Prevention\n          . Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. Available at: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html. Accessed June 9, 2021"},{"issue":"4","key":"2025072309471910400_B51","doi-asserted-by":"crossref","first-page":"e2021053745","DOI":"10.1542\/peds.2021-053745","article-title":"Recommendations for prevention and control of influenza in children, 2021\u20132022","volume":"148","author":"Committee on Infectious Diseases","year":"2021","journal-title":"Pediatrics"},{"issue":"8","key":"2025072309471910400_B52","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/infdis\/jiw105","article-title":"Modest waning of influenza vaccine efficacy and antibody titers during the 2007-2008 influenza season","volume":"214","author":"Petrie","year":"2016","journal-title":"J Infect Dis"},{"issue":"5","key":"2025072309471910400_B53","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/cid\/ciw816","article-title":"Intraseason waning of influenza vaccine protection: evidence from the US Influenza Vaccine Effectiveness Network, 2011\u201312 through 2014\u201315","volume":"64","author":"Ferdinands","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2025072309471910400_B54","doi-asserted-by":"crossref","first-page":"20388","DOI":"10.2807\/ese.18.05.20388-en","article-title":"Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011\/12","volume":"18","author":"Castilla","year":"2013","journal-title":"Euro Surveill"},{"issue":"5","key":"2025072309471910400_B55","doi-asserted-by":"crossref","first-page":"20390","DOI":"10.2807\/ese.18.05.20390-en","article-title":"Low and decreasing vaccine effectiveness against influenza A(H3) in 2011\/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study","volume":"18","author":"Kissling","year":"2013","journal-title":"Euro Surveill"},{"issue":"1","key":"2025072309471910400_B56","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.vaccine.2014.06.052","article-title":"Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season","volume":"33","author":"Belongia","year":"2015","journal-title":"Vaccine"},{"issue":"33","key":"2025072309471910400_B57","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1016\/j.vaccine.2016.05.034","article-title":"Influenza vaccine effectiveness: maintained protection throughout the duration of influenza seasons 2010-2011 through 2013-2014","volume":"34","author":"Radin","year":"2016","journal-title":"Vaccine"},{"issue":"43","key":"2025072309471910400_B58","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1016\/j.vaccine.2017.09.035","article-title":"Waning protection of influenza vaccination during four influenza seasons, 2011\/2012 to 2014\/2015","volume":"35","author":"Puig-Barber\u00e0","year":"2017","journal-title":"Vaccine"},{"issue":"10","key":"2025072309471910400_B59","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/cid\/ciy770","article-title":"Intraseason waning of influenza vaccine effectiveness","volume":"68","author":"Ray","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"16","key":"2025072309471910400_B60","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2016.21.16.30201","article-title":"I-MOVE multicentre case-control study 2010\/11 to 2014\/15: is there within-season waning of influenza type\/subtype vaccine effectiveness with increasing time since vaccination?","volume":"21","author":"Kissling","year":"2016","journal-title":"Euro Surveill"},{"issue":"5","key":"2025072309471910400_B61","doi-asserted-by":"crossref","first-page":"20389","DOI":"10.2807\/ese.18.05.20389-en","article-title":"Vaccine effectiveness of 2011\/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection","volume":"18","author":"Pebody","year":"2013","journal-title":"Euro Surveill"},{"issue":"4","key":"2025072309471910400_B62","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/jpids\/piz077","article-title":"Influenza vaccine effectiveness among children for the 2017-2018 season","volume":"9","author":"Powell","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2025072309471910400_B63","volume-title":"CDC Yellow Book: Health Information for International Travel","author":"Centers for Disease Control and Prevention","year":"2020"},{"issue":"4","key":"2025072309471910400_B64","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.anai.2013.07.030","article-title":"Update on influenza vaccination of egg allergic patients","volume":"111","author":"Kelso","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"2025072309471910400_B65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.anai.2017.10.020","article-title":"Administration of influenza vaccines to egg allergic recipients: a practice parameter update 2017","volume":"120","author":"Greenhawt","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"2025072309471910400_B66","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1097\/AOG.0000000000002588","article-title":"ACOG committee opinion no. 732: influenza vaccination during pregnancy","volume":"131","author":"American College of Obstetricians and Gynecologists","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"5","key":"2025072309471910400_B67","doi-asserted-by":"crossref","first-page":"e20162883","DOI":"10.1542\/peds.2016-2883","article-title":"The concordance of parent and child immunization","volume":"139","author":"Robison","year":"2017","journal-title":"Pediatrics"},{"issue":"15","key":"2025072309471910400_B68","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1056\/NEJMoa0708630","article-title":"Effectiveness of maternal influenza immunization in mothers and infants","volume":"359","author":"Zaman","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"2025072309471910400_B69","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S1473-3099(16)30054-8","article-title":"Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"2025072309471910400_B70","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa1401480","article-title":"Influenza vaccination of pregnant women and protection of their infants","volume":"371","author":"Madhi","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"2025072309471910400_B71","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S1473-3099(17)30252-9","article-title":"Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial","volume":"17","author":"Steinhoff","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"2025072309471910400_B72","doi-asserted-by":"crossref","first-page":"e20152360","DOI":"10.1542\/peds.2015-2360","article-title":"Influenza in infants born to women vaccinated during pregnancy","volume":"137","author":"Shakib","year":"2016","journal-title":"Pediatrics"},{"issue":"3","key":"2025072309471910400_B73","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1080\/21645515.2017.1345385","article-title":"Influenza vaccination during pregnancy for prevention of influenza confirmed illness in the infants: a systematic review and meta-analysis","volume":"14","author":"Nunes","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"2025072309471910400_B74","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/cid\/ciy737","article-title":"Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: a multi-country retrospective test negative design study, 2010-2016","volume":"68","author":"Thompson","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025072309471910400_B75","doi-asserted-by":"crossref","first-page":"122","DOI":"10.12688\/f1000research.12473.1","article-title":"Prevention of influenza-related illness in young infants by maternal vaccination during pregnancy","volume":"7","author":"Nunes","year":"2018","journal-title":"F1000 Res"},{"issue":"5","key":"2025072309471910400_B76","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/INF.0000000000001914","article-title":"Maternal influenza immunization and prevention of severe clinical pneumonia in young infants: analysis of randomized controlled trials conducted in Nepal, Mali, and South Africa","volume":"37","author":"Omer","year":"2018","journal-title":"Pediatr Infect Dis J"},{"issue":"52","key":"2025072309471910400_B77","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.1016\/j.vaccine.2018.10.088","article-title":"Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women","volume":"36","author":"Munoz","year":"2018","journal-title":"Vaccine"},{"issue":"3","key":"2025072309471910400_B78","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/AOG.0b013e318263a278","article-title":"Effect of influenza vaccination in the first trimester of pregnancy","volume":"120","author":"Sheffield","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"5","key":"2025072309471910400_B79","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/AOG.0000000000001068","article-title":"Maternal influenza vaccination and risk for congenital malformations: a systematic review and meta-analysis","volume":"126","author":"Polyzos","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"11","key":"2025072309471910400_B80","doi-asserted-by":"crossref","first-page":"e4296","DOI":"10.1093\/cid\/ciaa845","article-title":"Seasonal influenza vaccination during pregnancy and the risk of major congenital malformations in live-born infants: a 2010-2016 historical cohort study","volume":"73","author":"Peppa","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"44","key":"2025072309471910400_B81","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1016\/j.vaccine.2013.08.097","article-title":"Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants","volume":"31","author":"Chambers","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"2025072309471910400_B82","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jpeds.2014.01.037","article-title":"Maternal influenza vaccine and risks for preterm or small for gestational age birth","volume":"164","author":"Nordin","year":"2014","journal-title":"J Pediatr"},{"issue":"37","key":"2025072309471910400_B83","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1016\/j.vaccine.2016.06.054","article-title":"Safety of the 2010-11, 2011-12, 2012-13, and 2013-14 seasonal influenza vaccines in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS","volume":"34","author":"Chambers","year":"2016","journal-title":"Vaccine"},{"issue":"40","key":"2025072309471910400_B84","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1016\/j.vaccine.2017.06.069","article-title":"Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12","volume":"35","author":"Donahue","year":"2017","journal-title":"Vaccine"},{"issue":"44","key":"2025072309471910400_B85","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.1016\/j.vaccine.2019.09.035","article-title":"Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15","volume":"37","author":"Donahue","year":"2019","journal-title":"Vaccine"},{"key":"2025072309471910400_B86","unstructured":"Centers for Disease Control and Prevention\n          . Flu and Tdap vaccination coverage among pregnant women \u2013 United States, April 2021. Available at: https:\/\/www.cdc.gov\/flu\/fluvaxview\/pregnant-women-apr2021.htm. Accessed April 10, 2022"},{"issue":"35","key":"2025072309471910400_B87","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1016\/j.vaccine.2021.07.028","article-title":"Racial disparities in influenza immunization during pregnancy in the United States: a narrative review of the evidence for disparities and potential interventions","volume":"39","author":"Callahan","year":"2021","journal-title":"Vaccine"},{"issue":"41","key":"2025072309471910400_B88","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1016\/j.vaccine.2021.08.091","article-title":"Vaccine exposure during pregnancy among privately and publicly insured women in the United States, 2016\u20132018","volume":"39","author":"Moll","year":"2021","journal-title":"Vaccine"},{"key":"2025072309471910400_B89","doi-asserted-by":"crossref","first-page":"106531","DOI":"10.1016\/j.ypmed.2021.106531","article-title":"Disparities in maternal influenza immunization among women in rural and urban areas of the United States","volume":"147","author":"Kaur","year":"2021","journal-title":"Prev Med"},{"issue":"8","key":"2025072309471910400_B90","doi-asserted-by":"crossref","first-page":"e70867","DOI":"10.1371\/journal.pone.0070867","article-title":"IgA and neutralizing antibodies to influenza a virus in human milk: a randomized trial of antenatal influenza immunization","volume":"8","author":"Schlaudecker","year":"2013","journal-title":"PLoS One"},{"key":"2025072309471910400_B91","unstructured":"US Department of Health and Human Services, Office of Disease Prevention and Health Promotion\n          . Healthy People 2020 topics & objectives\u2013immunization and infectious diseases. Available at: https:\/\/www.healthypeople.gov\/2020\/topics-objectives\/topic\/immunization- and-infectious-diseases. Accessed June 9, 2021"},{"issue":"1","key":"2025072309471910400_B92","doi-asserted-by":"crossref","first-page":"e2020047092","DOI":"10.1542\/peds.2020-047092","article-title":"Pediatric vaccination during the COVID-19 pandemic","volume":"148","author":"Ackerson","year":"2021","journal-title":"Pediatrics"},{"issue":"20","key":"2025072309471910400_B93","doi-asserted-by":"crossref","first-page":"630","DOI":"10.15585\/mmwr.mm6920e1","article-title":"Decline in child vaccination coverage during the COVID-19 pandemic \u2013 Michigan Care Improvement Registry, May 2016-May 2020","volume":"69","author":"Bramer","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"2025072309471910400_B94","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamapediatrics.2020.4733","article-title":"Number of childhood and adolescent vaccinations administered before and after the COVID-19 outbreak in Colorado","volume":"175","author":"O\u2019Leary","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"19","key":"2025072309471910400_B95","doi-asserted-by":"crossref","first-page":"591","DOI":"10.15585\/mmwr.mm6919e2","article-title":"Effects of the COVID-19 pandemic on routine pediatric vaccine ordering and administration\u2014United States, 2020","volume":"69","author":"Santoli","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025072309471910400_B96","unstructured":"Centers for Disease Control and Prevention\n          . Weekly flu vaccination dashboard. Available at: https:\/\/www.cdc.gov\/flu\/fluvaxview\/dashboard\/vaccination-dashboard.html. Accessed March 31, 2022"},{"issue":"31","key":"2025072309471910400_B97","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1016\/j.vaccine.2021.06.041","article-title":"Early influenza vaccination rates decline in children during the COVID-19 pandemic","volume":"39","author":"Fogel","year":"2021","journal-title":"Vaccine"},{"issue":"3","key":"2025072309471910400_B98","doi-asserted-by":"crossref","first-page":"e21607","DOI":"10.2196\/21607","article-title":"Consumer reported care deferrals due to the COVID-19 pandemic, and the role and potential of telemedicine: cross-sectional analysis","volume":"6","author":"Atherly","year":"2020","journal-title":"JMIR Public Health Surveill"},{"key":"2025072309471910400_B99","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.acap.2021.02.001","article-title":"Childhood and adolescent vaccination in alternative settings","volume":"21","author":"Hofstetter","year":"2021","journal-title":"Acad Pediatr"},{"issue":"7","key":"2025072309471910400_B100","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/PEC.0000000000001869","article-title":"Parent intent and willingness to immunize children against influenza in the pediatric emergency department","volume":"35","author":"Hart","year":"2019","journal-title":"Pediatr Emerg Care"},{"issue":"6","key":"2025072309471910400_B101","doi-asserted-by":"crossref","first-page":"e20154335","DOI":"10.1542\/peds.2015-4335","article-title":"Immunization data exchange with electronic health records","volume":"137","author":"Stockwell","year":"2016","journal-title":"Pediatrics"},{"issue":"1","key":"2025072309471910400_B102","first-page":"CD003941","article-title":"Patient reminder and recall interventions to improve immunization rates","volume":"1","author":"Jacobson Vann","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2025072309471910400_B103","doi-asserted-by":"crossref","first-page":"e20182580","DOI":"10.1542\/peds.2018-2580","article-title":"Office-based educational handout for influenza vaccination: a randomized controlled trial","volume":"144","author":"Scott","year":"2019","journal-title":"Pediatrics"},{"issue":"1","key":"2025072309471910400_B104","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amepre.2018.04.010","article-title":"Addressing parents\u2019 vaccine concerns: a randomized trial of a social media intervention","volume":"55","author":"Daley","year":"2018","journal-title":"Am J Prev Med"},{"issue":"6","key":"2025072309471910400_B105","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.vaccine.2019.12.010","article-title":"Be inFLUential: evaluation of a multifaceted intervention to increase influenza vaccination rates among pediatric inpatients","volume":"38","author":"Rao","year":"2020","journal-title":"Vaccine"},{"issue":"1","key":"2025072309471910400_B106","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1542\/peds.2014-2616","article-title":"Registry-linked electronic influenza vaccine provider reminders: a cluster-crossover trial","volume":"135","author":"Stockwell","year":"2015","journal-title":"Pediatrics"},{"issue":"1","key":"2025072309471910400_B107","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/MOP.0000000000000843","article-title":"Evidence-based strategies to increase vaccination uptake: a review","volume":"32","author":"Cataldi","year":"2020","journal-title":"Curr Opin Pediatr"},{"issue":"20","key":"2025072309471910400_B108","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.vaccine.2017.03.077","article-title":"Clinician-parent discussions about influenza vaccination of children and their association with vaccine acceptance","volume":"35","author":"Hofstetter","year":"2017","journal-title":"Vaccine"},{"issue":"1","key":"2025072309471910400_B109","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1542\/peds.2011-2937","article-title":"Immunizing parents and other close family contacts in the pediatric office setting","volume":"129","author":"Lessin","year":"2012","journal-title":"Pediatrics"},{"key":"2025072309471910400_B110","unstructured":"Centers for Disease Control and Prevention\n          . Influenza vaccination coverage among health care personnel \u2014 United States, 2020\u201321 influenza season 2021. Available at: https:\/\/www.cdc.gov\/flu\/fluvaxview\/hcp-coverage_ 1920-21-estimates.htm. Accessed April 14, 2022"},{"issue":"4","key":"2025072309471910400_B111","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1017\/ice.2018.9","article-title":"Protecting healthcare personnel in outpatient settings: the influences of mandatory versus nonmandatory influenza vaccination policies on workplace absenteeism during multiple respiratory virus seasons","volume":"39","author":"Frederick","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2025072309471910400_B112","unstructured":"Centers for Disease Control and Prevention\n          . Influenza antiviral medications. Available at: www.cdc.gov\/flu\/professionals\/antivirals\/index.htm. Accessed April 14, 2022"},{"issue":"6","key":"2025072309471910400_B113","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy866","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2018 update diagnosis, treatment, chemoprophylaxis and institutional outbreak management of seasonal influenza","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2025072309471910400_B114","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40265-018-0899-1","article-title":"Baloxavir: first global approval","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"2025072309471910400_B115","unstructured":"US Food and Drug Administration\n          . Approval package for XOFLUZA. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/210854 Orig1s001.pdf. Accessed May 29, 2022"},{"issue":"8","key":"2025072309471910400_B116","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/INF.0000000000002747","article-title":"Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2)","volume":"39","author":"Baker","year":"2020","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2025072309471910400_B117","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/03007995.2020.1839400","article-title":"Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a Bayesian network meta-analysis","volume":"37","author":"Taieb","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"2025072309471910400_B118","unstructured":"F. Hoffman-LaRoche Ltd\n          . Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person. Available at: https:\/\/www.roche.com\/media\/releases\/med-cor-2020-11-24.htm. Accessed June 9, 2021"},{"issue":"4","key":"2025072309471910400_B119","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1915341","article-title":"Baloxavir marboxil for prophylaxis against influenza in household contacts","volume":"383","author":"Ikematsu","year":"2020","journal-title":"N Engl J Med"},{"key":"2025072309471910400_B120","unstructured":"US Food and Drug Administration\n          . Baloxavir package insert. Available at: https:\/\/www.gene.com\/download\/pdf\/xofluza_prescribing.pdf. Accessed August 22, 2022"},{"issue":"5","key":"2025072309471910400_B121","doi-asserted-by":"crossref","first-page":"e20162727","DOI":"10.1542\/peds.2016-2727","article-title":"Intravenous zanamivir in hospitalized patients with influenza","volume":"140","author":"Bradley","year":"2017","journal-title":"Pediatrics"},{"issue":"9979","key":"2025072309471910400_B122","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet"},{"key":"2025072309471910400_B123","first-page":"CD008965","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children","volume":"1","author":"Jefferson","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2025072309471910400_B124","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/cid\/cix1040","article-title":"Efficacy and safety of oseltamivir in children: systematic review and individual patient data meta-analysis of randomized controlled trials","volume":"66","author":"Malosh","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2025072309471910400_B125","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1093\/cid\/cix1150","article-title":"Oseltamivir treatment of influenza in children","volume":"66","author":"Uyeki","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2025072309471910400_B126","first-page":"CD002744","article-title":"Neuraminidase inhibitors for preventing and treating influenza in children (published trials only)","volume":"2012","author":"Wang","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2025072309471910400_B127","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1017\/S0950268818000663","article-title":"Effectiveness of antiviral treatment in preventing death in severe hospitalised influenza cases over six seasons","volume":"146","author":"Dom\u00ednguez","year":"2018","journal-title":"Epidemiol Infect"},{"issue":"7","key":"2025072309471910400_B128","doi-asserted-by":"crossref","first-page":"512","DOI":"10.7326\/0003-4819-156-7-201204030-00411","article-title":"Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies","volume":"156","author":"Hsu","year":"2012","journal-title":"Ann Intern Med"},{"issue":"5","key":"2025072309471910400_B129","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"10","key":"2025072309471910400_B130","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/cix127","article-title":"Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(\/H1N1)pdm09 at high risk of hospitalization: an individual participant data metaanalysis","volume":"64","author":"Venkatesan","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2025072309471910400_B131","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/17512433.2021.1917378","article-title":"Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials","volume":"14","author":"Tejada","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"2025072309471910400_B132","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/cid\/ciab625","article-title":"Reducing influenza virus transmission: the potential value of antiviral treatment","volume":"74","author":"Hayden","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025072309471910400_B133","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2016.07.007","article-title":"A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama","volume":"133","author":"Dawood","year":"2016","journal-title":"Antiviral Res"},{"issue":"6","key":"2025072309471910400_B134","doi-asserted-by":"crossref","first-page":"e1539","DOI":"10.1542\/peds.2013-2149","article-title":"Neuraminidase inhibitors for critically ill children with influenza","volume":"132","author":"Louie","year":"2013","journal-title":"Pediatrics"},{"issue":"4","key":"2025072309471910400_B135","doi-asserted-by":"crossref","first-page":"e2021050417","DOI":"10.1542\/peds.2021-050417","article-title":"Influenza antiviral treatment and length of stay","volume":"148","author":"Campbell","year":"2021","journal-title":"Pediatrics"},{"issue":"5","key":"2025072309471910400_B136","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/jcpt.13203","article-title":"Comparison of double-dose vs standard-dose oseltamivir in the treatment of influenza: a systematic review and meta-analysis","volume":"45","author":"Li","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"2025072309471910400_B137","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/cid\/ciy860","article-title":"Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes","volume":"69","author":"Katzen","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2025072309471910400_B138","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/cid\/ciy163","article-title":"A randomized study evaluating the effectiveness of oseltamivir initiated at the time of hospital admission in adults hospitalized with influenza-associated lower respiratory tract infections","volume":"67","author":"Ramirez","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2025072309471910400_B139","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1093\/jpids\/piy033","article-title":"Influenza-associated acute necrotizing encephalopathy in siblings","volume":"7","author":"Howard","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"4","key":"2025072309471910400_B140","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/pds.4721","article-title":"Oseltamivir phosphate-lifting the restriction on its use to treat teenagers with influenza in Japan","volume":"28","author":"Takeuchi","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"2025072309471910400_B141","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12325-012-0050-8","article-title":"Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review","volume":"29","author":"Toovey","year":"2012","journal-title":"Adv Ther"},{"issue":"2","key":"2025072309471910400_B142","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/irv.12927","article-title":"Influenza clinical testing and oseltamivir treatment in hospitalized children with acute respiratory illness, 2015\u20132016","volume":"16","author":"Hamdan","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"issue":"4","key":"2025072309471910400_B143","doi-asserted-by":"crossref","first-page":"e2020049672","DOI":"10.1542\/peds.2020-049672","article-title":"Antiviral use in Canadian children hospitalized for influenza","volume":"148","author":"Mehta","year":"2021","journal-title":"Pediatrics"},{"issue":"3","key":"2025072309471910400_B144","doi-asserted-by":"crossref","first-page":"1800698","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800698","article-title":"Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018","volume":"24","author":"Takashita","year":"2019","journal-title":"Euro Surveill"},{"issue":"10","key":"2025072309471910400_B145","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2025072309471910400_B146","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"2025072309471910400_B147","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/cid\/ciz908","article-title":"Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes","volume":"71","author":"Hirotsu","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2025072309471910400_B148","first-page":"346","article-title":"Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza","volume":"221","author":"Uehara","year":"2020","journal-title":"J Infect Dis"},{"key":"2025072309471910400_B149","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.02.007","article-title":"Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012\u20132018","volume":"164","author":"Koszalka","year":"2019","journal-title":"Antiviral Res"},{"issue":"12","key":"2025072309471910400_B150","doi-asserted-by":"crossref","first-page":"1900170","DOI":"10.2807\/1560-7917.ES.2019.24.12.1900170","article-title":"Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019","volume":"24","author":"Takashita","year":"2019","journal-title":"Euro Surveill"},{"issue":"3","key":"2025072309471910400_B151","doi-asserted-by":"crossref","first-page":"1800666","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800666","article-title":"Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016\/17 and 2017\/18 seasons","volume":"24","author":"Gubareva","year":"2019","journal-title":"Euro Surveill"},{"issue":"6","key":"2025072309471910400_B152","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/infdis\/jiaa164","article-title":"Treatment-emergent influenza virus PA substitutions independent of those at I38 associated with reduced baloxavir susceptibility and virus rebound in trials of baloxavir marboxil","volume":"222","author":"Ince","year":"2020","journal-title":"J Infect Dis"},{"key":"2025072309471910400_B153","doi-asserted-by":"crossref","first-page":"104718","DOI":"10.1016\/j.antiviral.2020.104718","article-title":"Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018","volume":"175","author":"Takashita","year":"2020","journal-title":"Antiviral Res"},{"key":"2025072309471910400_B154","doi-asserted-by":"crossref","first-page":"105281","DOI":"10.1016\/j.antiviral.2022.105281","article-title":"Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018\u20132020","volume":"200","author":"Govorkova","year":"2022","journal-title":"Antiviral Res"},{"issue":"1","key":"2025072309471910400_B155","doi-asserted-by":"crossref","first-page":"e20193852","DOI":"10.1542\/peds.2019-3852","article-title":"Parental hesitancy about routine childhood and influenza vaccinations: a national survey","volume":"146","author":"Kempe","year":"2020","journal-title":"Pediatrics"},{"issue":"6","key":"2025072309471910400_B156","doi-asserted-by":"crossref","first-page":"e2020007609","DOI":"10.1542\/peds.2020-007609","article-title":"Parental vaccine hesitancy and childhood influenza vaccination","volume":"146","author":"Santibanez","year":"2020","journal-title":"Pediatrics"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2022-059275\/1562060\/peds_2022059275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2022-059275\/1562060\/peds_2022059275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T13:47:39Z","timestamp":1753278459000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/150\/4\/e2022059275\/189387\/Recommendations-for-Prevention-and-Control-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":156,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,9,6]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2022-059275","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"article-number":"e2022059275"}}